

Attorney Docket No.: 6544.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Persson et al.

Serial No.: 10/669,537

Group Art Unit: To be assigned

Filed: September 24, 2003

Examiner: To be assigned

For: Human Coagulation Factor VII Polypeptides

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I hereby certify that the attached correspondence comprising:

1. Supplemental Information Disclosure Statement
2. Form PTO-1449
3. Copy of Reference (10)


is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on **February 11, 2004**

Dolly Kapadia
(name of person mailing paper)

Dolly Kapadia
(signature of person mailing paper)


 FORM PTO-1449
 (Rev. 7-2003)

 U.S. DEPARTMENT OF COMMERCE
 PATENT AND TRADEMARK OFFICE

Atty. Docket No. 6544.200-US

Serial No. 10/669,537

 INFORMATION DISCLOSURE
 STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant Persson et al.

Filing Date September 24, 2003

Group 1653

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	US Patent Appl. Publ. 2003/0130191 A1	7/10/03	Persson et al.	514	12	
	US Patent Appl. Publ. 2003/0170863 A1	9/11/03	Persson et al.	435	226	

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 02/077218 A1	10/3/02	PCT				
	WO 03/027147 A2	4/3/03	PCT				
	JP 2001/061479	3/13/01	JP			X	
	JP 10/59866A	3/3/98	JP			X	


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Persson et al., The Journal of Biological Chemistry, Vol. 276, No. 31, pages 29195-29199 (2001)
	Peyvandi et al., Throm. Haemost., Vol. 84, pages 250-257 (2000)
	Peyvandi et al., Throm. Haemost., Vol. 88, pages 750-755 (2002)
	International Search Report mailed 2/5/04

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Attorney Docket No.: 6544.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Persson et al.

Application No.: 10/669,537

Group Art Unit: 1653

Filed: September 24, 2003

Examiner: To be assigned

For: Human Coagulation Factor VII Polypeptides

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no material references other than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

The references are as follows:


1. U.S. Patent Application Publication No. US 2003/0130191 A1
2. U.S. Patent Application Publication No. US 2003/0170863 A1
3. WO 02/077218 A1
4. WO 03/027147 A2
5. JP 2001/061479 (Original and Translation)
6. JP 10/59866A (Translation)
7. Persson et al., The Journal of Biological Chemistry, Vol. 276, No. 31, pages 29195-29199 (2001)
8. Peyvandi et al., Throm. Haemost., Vol. 84, pages 250-257 (2000)
9. Peyvandi et al., Throm. Haemost., Vol. 88, pages 750-755 (2002)
10. International Search Report mailed 2/5/04

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed **within** three months of the filing date of a national application or date of entry into the national stage of an international application or **before** the mailing date of a first Office action on the merits, or **before** the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due. However, please charge any fees should they be required, to Novo Nordisk Pharmaceuticals, Inc. Deposit Account No. 14-1447.

Date: March 8, 2004

Respectfully submitted,


Reza Green, Reg. No. 38,475
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

Use the following customer number for all correspondence regarding this application.

23650

PATENT TRADEMARK OFFICE